Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-20
2009-12-08
Tate, Christopher R (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S023000, C424S198100
Reexamination Certificate
active
07629312
ABSTRACT:
The invention provides a method for administering streptolysin O for treatment of various conditions including connective tissue disorders, reproductive fibroses and conditions mediated by the CD44 receptor. The invention also provides methods for protecting nerve cells from the effects of neurotoxic agents by the administration of streptolysin O.
REFERENCES:
patent: 5240846 (1993-08-01), Collins et al.
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5420116 (1995-05-01), Puchelle et al.
patent: 5470838 (1995-11-01), von Borstel et al.
patent: 5576289 (1996-11-01), McMichael
patent: 5726160 (1998-03-01), McMichael
patent: 5736508 (1998-04-01), McMichael
patent: 5948768 (1999-09-01), McMichael et al.
patent: 5955442 (1999-09-01), McMichael
patent: 6096721 (2000-08-01), McMichael
patent: 6303127 (2001-10-01), McMichael et al.
patent: 6447820 (2002-09-01), Niazi
patent: WO-9211016 (1992-07-01), None
patent: WO-9312240 (1993-06-01), None
patent: WO-9423048 (1994-10-01), None
patent: WO-9525800 (1995-09-01), None
patent: WO-9632138 (1996-10-01), None
patent: WO-9640059 (1996-12-01), None
patent: WO-9705195 (1997-02-01), None
Alton, E.W.F.W. et al., “Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice,” Chemical Abstracts, 119:62 (1993) (Abstract 217089w).
Askanas et al., “A New Program for Investigating Adult Human Skeletal Muscle Grown Aneurally in Tissue Culture,” Neurology, 25:58-67 (1975).
Badesch et al., “Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease, A Randomized, Controlled Trial,” Ann. Intern. Med., 132:425-434 (2000).
Baker, R.C., “Pitfalls in Diagnosing Acute Otitis Media,” Pediatric Annals, 20:591-593, 596-598 (1991).
Barst et al., “A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) With Conventional Therapy for Primary Pulmonary Hypertension,” N. Eng. J. Med., 334:296-301 (1996).
Berkow, R. (Ed.), The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Merck Research Laboratories, Division of Merck & Co., Inc., Rahway, N.J. pp. 600-602 (1992).
Berman, S., “Otitis Media in Developing Countries,” Pediatrics, 96:126-131 (1995).
Canonico, A.E. et al., “Expression Of A Cmv Promoter Driven Human ?-1 Antitrypsin Gene In Cultured Lung Endothelial Cells And In The Lungs Of Rabbits,” Clin. Res., 39(2): 219A (1991).
Carman et al., “A Primary Care Approach to the Patient with Claudication,” Am. Fam. Physician, 61:1027-1032 (2000).
Cunningham, M.W., “Pathogenesis of Group A Streptococcal Infections,” Clin. Microbiol. 13:470-511 (2000).
Dagan, R. et al., “Treatment Failures in Otitis Media—What Can We Learn?,” Ear, Nose and Throat J., 77:16-21 (1998).
Dawson et al., “Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication,” Circulation, 98:678-686 (1998).
DeGraves et al., “Economics of Mastitis and Mastitis Control,” The Veterinary Clinics of North America—Food Animal Practice Update on Bovine Mastitis, 9:421-434 (1993).
Flotte, T.R., et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector,” Chemical Abstracts, 120:229(1994) (Abstract 46918e).
Furth et al., “Gene Transfer into Somatic Tissues by Jet Injection,” Analytical Biochemistry, 205:365-368 (1992).
Gardner et al., “Exercise Rehabilitation Programs for the Treatment of Claudication Pain: A Meta Analysis,” JAMA, 274:975-980 (1995).
Gent et al., A Randomised, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE), Lancet, 348:1329-1339 (1996).
Goldhaber et al., “Low-Dose and Subsequent Peripheral Arterial Surgery in the Physicians' Health Study,” Lancet, 340:143-145 (1992).
Harrison et al., “Structural Features of Interstitial Lung Disease in Systemic Sclerosis,” Am. Rev. Respir. Dis., 144:706-713 (1991).
Hood et al., “Management of Intermittent Claudication with Pentoxifylline: Meta-Analysis of Randomised Controlled Trials,” CMAJ, 155:1053-1059 (1996).
International Search Report corresponding to International Patent Application Serial No. PCT/US04/01887 dated Aug. 26, 2004, 2 pages.
Janzon et al., “Prevention of Myocardial Infarction and Stroke in Patients with Intermittent Claudication; Effects of Ticlopidine. Results from STMS, the Swedish Ticlopidine Multicentre Study,” J. Intern.Med., 27:301-308 (1990).
Jarrow et al., “Peyronie's Disease and Radical Prostatectomy: Is There A Link?,” J. of Urology, 158:1388-1390 (1997).
Karver, S.B., “Otitis Media,” Ear, Nose and Throat Disorders, 25:619-632(1998).
Kiessling et al., “Antineuronal Antibodies in Movement Disorders,” Pediatrics, 92:39-43 (1993).
Klein, J.O., “Otitis Media,” Clinical Infectious Disease, 19:823-833 (1994).
Ledley, F.D., “Non-viral gene therapy,” Current Opinion in Biotechnology, 5: 626-636 (1994).
Ledley, F.D. “Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products,” Human Gene Therapy, 6: 1129-1144 (Sep. 1995).
Marshall, E., “Gene Therapy's Growing Pains,” Science, 269: 1050-1055 (1995).
Patterson et al., “Value of a Supervised Exercise Program for the Therapy of Arterial Claudication,” J. Vasc. Surg., 25:312-319 (1997).
Razin et al., “Protein Kinases C-β and C-e Link the Mast Cell High-Affinity Receptor for IgE to the Expression of c-fos and c-jun,” Proc. Natl. Acad. Sci. (USA), 91:7722-7726 (1994).
Rosenfeld, J. et al., “Acute Otitis Media in Children,” Primary Care; Clinics in Office Practice, 23(4):677-686(1996).
Rosenfeld, M.A. et al., “Adenovirus-Mediated Transfer of a Recombinant a1-Antitrypsin Gene to the Lung Epithelium in Vivo,” Science 252: 431-434(1991).
Ruiz et al., “Streptolysin O and Adherence Synergistically Modulate Proinflammatory Responses of Keratinocytes to Group A Streptococci,” Mol. Microbiol. 27:337-346 (1997).
Schrager et al., “Hyaluronic Acid Capsule Modulates M Protein-Mediated Adherence and Acts as a Ligand for Attachment of Group A Streptococcus to CD44 on Human Keratinocytes,” J. Clin. Investig. 101:1708-1716 (1998).
Siebold et al., “Recombinant Human Relaxin in the Treatment of Scleroderma, A Randomized, Double-Blind, Placebo-Controlled Trial,” Ann. Intern. Med., 132:871-879 (2000).
Silver et al., “Evaluation and Management of Scleroderma Lung Disease Using Bronchoalveolar Lavage,” Am. J. Med., 88:470-476 (1990).
Taranta et al., “The Relationship of Sydenham's Chorea to Infection with Group A Stretococci,” Am. J. Med., 20:170-175 (1956).
Unemori et al., “Relaxin Modulates Synthesis and Secretion of Procollagenase and Collagen by Human Dermal Fibroblasts,” J. Biol. Chem., 265:10681-10685 (1990).
Visa et al., “The Value of Fasciectomy in the Surgical Approach of the Dupuytren's Disease,” Romanian Journal of Hand and Reconstructive Microsurgery, 5:9-13 (2000).
Wallaert et al., “Subclinical Pulmonary Involvement in Collagen-Vascular Diseases Assessed by Bronchalveolar Lavage,” Am. Rev. Respir. Dis., 133:574-580 (1986).
White et al., “Cyclophosphamide is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis,” Ann. Intern. Med., 132:947-954 (2000).
Marshall & Gerstein & Borun LLP
Milkhaus Laboratory, Inc.
Tate Christopher R
Winston Randall
LandOfFree
Method of treatment of tendonitis by administration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of tendonitis by administration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of tendonitis by administration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133155